IBOV 175,135.41 ▲ 0.31% IPSA 11,470.79 ▲ 0.89% IPC MEX 65,829.98 ▼ 0.55% MERVAL 3,001,209 — 0.00% COLCAP 2,489.80 ▼ 0.59% BVL PERÚ 60,629.82 ▲ 0.25% USD/BRL5.19▲ 0.48% USD/MXN16.98▼ 0.03% USD/CLP924.87▼ 0.17% USD/COP3,183▲ 1.75% USD/PEN3.35▼ 0.11% USD/ARS1,512▼ 0.02% USD/UYU40.25▲ 1.53% USD/PYG5,905▲ 0.48% USD/BOB11.78▲ 3.59% USD/DOP58.61▲ 0.96% USD/CRC448.38▲ 1.62% USD/GTQ7.63▲ 2.27% USD/HNL26.83▲ 1.77% USD/NIO36.62▼ 0.02% USD/VES789.69▼ 0.08% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 1.14% EUR/BRL6.04▲ 0.77% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 175,135.41 ▲ 0.31% IPSA 11,470.79 ▲ 0.89% IPC MEX 65,829.98 ▼ 0.55% MERVAL 3,001,209 — 0.00% COLCAP 2,489.80 ▼ 0.59% BVL PERÚ 60,629.82 ▲ 0.25% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Friday, August 28, 2026

Crypto Pacific

Australia allows psilocybin and ecstasy to be prescribed for mental health treatment

By · July 1, 2023 · 1 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

Australia has become the first country to permit the prescription of psychedelic drugs psilocybin (found in hallucinogenic mushrooms) and MDMA (commonly known as ecstasy) for treating mental health conditions.

The Therapeutic Goods Administration (TGA) approved the regulation in February, which came into effect on Saturday.

Psychiatrists will now have the ability to prescribe these substances, which are typically used recreationally and illegally.

Under the new regulation, synthetic MDMA (3,4-methylenedioxymethamphetamine) can be prescribed to treat post-traumatic stress syndrome, while psilocybin can be used for depression cases that have not responded to other treatments.

Australia allows psilocybin and ecstasy to be prescribed for mental health treatment. (Photo Internet reproduction)
Australia allows psilocybin and ecstasy to be prescribed for mental health treatment. (Photo Internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The TGA, responsible for drug regulation in Australia, states that there is sufficient evidence for the potential benefits of these substances in these specific conditions.

While other countries allow the therapeutic use of these drugs, Australia is the first to regulate their use nationwide.

Psychiatrists must obtain TGA approval and have their prescriptions reviewed by an ethical research committee before prescribing drugs containing these substances.

The TGA acknowledges the limited options available for patients with treatment-resistant mental illnesses but emphasizes the need for controls to monitor potential adverse effects.

Outside of the approved uses for these two conditions, psilocybin and MDMA remain prohibited substances.

Although there are currently no authorized products containing these substances in the Australian market, licensed psychiatrists will be allowed to supply “unapproved drugs” containing psilocybin and MDMA under the TGA’s supervision.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.